

WISCONSIN LEGISLATIVE COUNCIL STAFF

RULES CLEARINGHOUSE

Ronald Sklansky
Director
(608) 266-1946

Richard Sweet
Assistant Director
(608) 266-2982



David J. Stute, Director
Legislative Council Staff
(608) 266-1304

One E. Main St., Ste. 401
P.O. Box 2536
Madison, WI 53701-2536
FAX: (608) 266-3830

CLEARINGHOUSE RULE 97-137

Comments

[NOTE: All citations to “Manual” in the comments below are to the Administrative Rules Procedures Manual, prepared by the Revisor of Statutes Bureau and the Legislative Council Staff, dated October 1994.]

2. Form, Style and Placement in Administrative Code

a. Although the format in which Clearinghouse Rule 97-137 is presented provides the reader with a complete view of s. Ins 3.53, the appropriate method to effect the proposed changes in the rule would include the following treatment sections:

- (1) SECTION 1. Ins 3.53 (1) is amended to read:
- (2) SECTION 2. Ins 3.53 (3) (c) and (d) are repealed.
- (3) SECTION 3. Ins 3.53 (3) (e) to (i) are renumbered 3.53 (3) (c) to (g).
- (4) SECTION 4. Ins 3.53 (4) (e) is repealed and recreated to read:
- (5) SECTION 5. Ins 3.53 (4) (f) is repealed.
- (6) SECTION 6. Ins 3.53 (4) (g) is renumbered 3.53 (4) (f).
- (7) SECTION 7. Ins 3.53 (4) (g) Note is repealed.
- (8) SECTION 8. Ins 3.53 (4) (h) is renumbered 3.53 (4) (g) and 3.53 (4) (g) 2., as renumbered, is amended to read:

b. In s. Ins 3.53 (4) (e), the terms “Food and Drug Administration” and “National Committee for Clinical Laboratory” should not be capitalized. Also, parenthetical notations and

the notation “e.g.” should not be used. The parenthetical comments should be incorporated into the text of the rule. Further, it appears that the first occurrence of the word “which” in par. (e) 1., 2. and 3. should be deleted. [For example, see the structure of par. (e) 4.] In par. (e) 2., the word “and” should not be emphasized. Finally, in par. (e) 2., the second and third sentences should be written in the singular form. For example, the second sentence should read: “A specimen which is repeatedly reactive to an FDA-licensed HIV antigen test . . . assay.”